News from AGA

As part of Crohn’s and Colitis Awareness Week 2017 (Dec. 1-7), AGA participated in a congressional briefing sponsored by Takeda and the California Life Sciences Association highlighting advances in inflammatory bowel disease (IBD) therapies, as well as the barriers that patients face in receiving proper treatment for managing their disease.

Physician perspective

Michael Weinstein, MD, representing AGA and the Digestive Health Physicians Association, discussed how treatment options have changed considerably since he began practicing in the 1980s when the only treatment options were immunosuppressive drugs or high-dose steroids that led to dangerous side effects. He highlighted the burden that physicians face with prior authorization practices, especially step therapy in which a patient is required to fail several therapies before being granted coverage to the preferred, physician-prescribed therapy. These insurance protocols can have dire effects on patient care and can be very disruptive to patients who may be so ill that they cannot work or go to school. Dr. Weinstein stated that the burden step therapy places on his practice requires him to have a full-time employee just to navigate the various insurance policies. Many small practices do not have the resources to handle these burdens. Read more from Dr. Weinstein in his op-ed from The Hill.

Patient perspective

Members of Congress and congressional staff heard compelling testimony from Kate Detwiler, an IBD patient who spoke of her family history of IBD, her experience with the disease, and how disruptive it has been to find the best provider and treatments to manage her disease. She and Dr. Weinstein both stressed the financial burdens that the disease puts on families and how limiting it can be to patients who are starting out in their careers or school.

Legislator perspective

Rep. Brad Weinstrup, R-OH, and Rep. Raul Ruiz, D-CA, addressed the briefing as the lead sponsors of HR 2077, the Restoring Patient’s Voice Act, which would provide patients and providers with a clear, equitable, and transparent appeals process when subject to step therapy protocols. Both Rep. Wenstrup and Rep. Ruiz are physicians and have seen the real-life consequences of these policies and their impact on patient care. Both representatives stressed that this is a bipartisan, commonsense solution to ensuring that patients have access to the care that they need when they need it.

AGA continues to advocate for support and passage of HR 2077 and thanks those members who have contacted their members of Congress to request their support. If you haven’t already, please call on your legislator to support this legislation. We will continue to work to garner additional support for the bill in this Congress.
 

[email protected]

As part of Crohn’s and Colitis Awareness Week 2017 (Dec. 1-7), AGA participated in a congressional briefing sponsored by Takeda and the California Life Sciences Association highlighting advances in inflammatory bowel disease (IBD) therapies, as well as the barriers that patients face in receiving proper treatment for managing their disease.

Physician perspective

Michael Weinstein, MD, representing AGA and the Digestive Health Physicians Association, discussed how treatment options have changed considerably since he began practicing in the 1980s when the only treatment options were immunosuppressive drugs or high-dose steroids that led to dangerous side effects. He highlighted the burden that physicians face with prior authorization practices, especially step therapy in which a patient is required to fail several therapies before being granted coverage to the preferred, physician-prescribed therapy. These insurance protocols can have dire effects on patient care and can be very disruptive to patients who may be so ill that they cannot work or go to school. Dr. Weinstein stated that the burden step therapy places on his practice requires him to have a full-time employee just to navigate the various insurance policies. Many small practices do not have the resources to handle these burdens. Read more from Dr. Weinstein in his op-ed from The Hill.

Patient perspective

Members of Congress and congressional staff heard compelling testimony from Kate Detwiler, an IBD patient who spoke of her family history of IBD, her experience with the disease, and how disruptive it has been to find the best provider and treatments to manage her disease. She and Dr. Weinstein both stressed the financial burdens that the disease puts on families and how limiting it can be to patients who are starting out in their careers or school.

Legislator perspective

Rep. Brad Weinstrup, R-OH, and Rep. Raul Ruiz, D-CA, addressed the briefing as the lead sponsors of HR 2077, the Restoring Patient’s Voice Act, which would provide patients and providers with a clear, equitable, and transparent appeals process when subject to step therapy protocols. Both Rep. Wenstrup and Rep. Ruiz are physicians and have seen the real-life consequences of these policies and their impact on patient care. Both representatives stressed that this is a bipartisan, commonsense solution to ensuring that patients have access to the care that they need when they need it.

AGA continues to advocate for support and passage of HR 2077 and thanks those members who have contacted their members of Congress to request their support. If you haven’t already, please call on your legislator to support this legislation. We will continue to work to garner additional support for the bill in this Congress.
 

[email protected]

As part of Crohn’s and Colitis Awareness Week 2017 (Dec. 1-7), AGA participated in a congressional briefing sponsored by Takeda and the California Life Sciences Association highlighting advances in inflammatory bowel disease (IBD) therapies, as well as the barriers that patients face in receiving proper treatment for managing their disease.

Physician perspective

Michael Weinstein, MD, representing AGA and the Digestive Health Physicians Association, discussed how treatment options have changed considerably since he began practicing in the 1980s when the only treatment options were immunosuppressive drugs or high-dose steroids that led to dangerous side effects. He highlighted the burden that physicians face with prior authorization practices, especially step therapy in which a patient is required to fail several therapies before being granted coverage to the preferred, physician-prescribed therapy. These insurance protocols can have dire effects on patient care and can be very disruptive to patients who may be so ill that they cannot work or go to school. Dr. Weinstein stated that the burden step therapy places on his practice requires him to have a full-time employee just to navigate the various insurance policies. Many small practices do not have the resources to handle these burdens. Read more from Dr. Weinstein in his op-ed from The Hill.

Patient perspective

Members of Congress and congressional staff heard compelling testimony from Kate Detwiler, an IBD patient who spoke of her family history of IBD, her experience with the disease, and how disruptive it has been to find the best provider and treatments to manage her disease. She and Dr. Weinstein both stressed the financial burdens that the disease puts on families and how limiting it can be to patients who are starting out in their careers or school.

Legislator perspective

Rep. Brad Weinstrup, R-OH, and Rep. Raul Ruiz, D-CA, addressed the briefing as the lead sponsors of HR 2077, the Restoring Patient’s Voice Act, which would provide patients and providers with a clear, equitable, and transparent appeals process when subject to step therapy protocols. Both Rep. Wenstrup and Rep. Ruiz are physicians and have seen the real-life consequences of these policies and their impact on patient care. Both representatives stressed that this is a bipartisan, commonsense solution to ensuring that patients have access to the care that they need when they need it.

AGA continues to advocate for support and passage of HR 2077 and thanks those members who have contacted their members of Congress to request their support. If you haven’t already, please call on your legislator to support this legislation. We will continue to work to garner additional support for the bill in this Congress.
 

[email protected]

Digestive Disease Week^® (DDW), taking place in Washington, D.C., June 2-5, is the gold standard digestive disease meeting. Attend to learn monumental developments in science and medicine, meet leaders in the field, network with colleagues, and attain practical takeaways that you can implement in your career. Visit www.ddw.org to register, for general meeting information, details about the host city, and much more.

On the DDW website, you can also register for the AGA Postgraduate Course taking place during DDW, June 2-3. The 2018 AGA Postgraduate Course will provide a comprehensive look at the latest medical, surgical, and technological advances over the past 12 months that aim to keep you up to date in a field that is rapidly changing. Each presenter will turn abstract ideas into concrete action items that you can immediately implement in your practice. At the end of the course, the take-home points will be compiled and distributed with the eSyllabus.

[email protected]

Digestive Disease Week^® (DDW), taking place in Washington, D.C., June 2-5, is the gold standard digestive disease meeting. Attend to learn monumental developments in science and medicine, meet leaders in the field, network with colleagues, and attain practical takeaways that you can implement in your career. Visit www.ddw.org to register, for general meeting information, details about the host city, and much more.

On the DDW website, you can also register for the AGA Postgraduate Course taking place during DDW, June 2-3. The 2018 AGA Postgraduate Course will provide a comprehensive look at the latest medical, surgical, and technological advances over the past 12 months that aim to keep you up to date in a field that is rapidly changing. Each presenter will turn abstract ideas into concrete action items that you can immediately implement in your practice. At the end of the course, the take-home points will be compiled and distributed with the eSyllabus.

[email protected]

Digestive Disease Week^® (DDW), taking place in Washington, D.C., June 2-5, is the gold standard digestive disease meeting. Attend to learn monumental developments in science and medicine, meet leaders in the field, network with colleagues, and attain practical takeaways that you can implement in your career. Visit www.ddw.org to register, for general meeting information, details about the host city, and much more.

On the DDW website, you can also register for the AGA Postgraduate Course taking place during DDW, June 2-3. The 2018 AGA Postgraduate Course will provide a comprehensive look at the latest medical, surgical, and technological advances over the past 12 months that aim to keep you up to date in a field that is rapidly changing. Each presenter will turn abstract ideas into concrete action items that you can immediately implement in your practice. At the end of the course, the take-home points will be compiled and distributed with the eSyllabus.

[email protected]

Make a tribute gift to honor someone whose life has been touched by GI research or celebrate a special occasion such as a birthday while supporting the AGA Research Awards Program through the AGA Research Foundation. A tribute gift will make your loved one feel special because it honors their passion, and also provides us with needed support in furthering basic digestive disease research.

•  Giving a gift to the AGA Research Foundation in memory of a loved one. A memorial gift is a meaningful way to celebrate the legacy of a family member, friend, or colleague.
•  Telling your friends and family members to donate to the AGA Research Foundation in YOUR honor.

Your next step

An honorary gift is a wonderful way to acknowledge someone’s vision for the future. To learn more about ways to recognize your honoree, visit our website at www.gastro.org/contribute or contact Harmony Excellent at 301-272-1602 or [email protected].

[email protected]

Make a tribute gift to honor someone whose life has been touched by GI research or celebrate a special occasion such as a birthday while supporting the AGA Research Awards Program through the AGA Research Foundation. A tribute gift will make your loved one feel special because it honors their passion, and also provides us with needed support in furthering basic digestive disease research.

•  Giving a gift to the AGA Research Foundation in memory of a loved one. A memorial gift is a meaningful way to celebrate the legacy of a family member, friend, or colleague.
•  Telling your friends and family members to donate to the AGA Research Foundation in YOUR honor.

Your next step

An honorary gift is a wonderful way to acknowledge someone’s vision for the future. To learn more about ways to recognize your honoree, visit our website at www.gastro.org/contribute or contact Harmony Excellent at 301-272-1602 or [email protected].

[email protected]

Make a tribute gift to honor someone whose life has been touched by GI research or celebrate a special occasion such as a birthday while supporting the AGA Research Awards Program through the AGA Research Foundation. A tribute gift will make your loved one feel special because it honors their passion, and also provides us with needed support in furthering basic digestive disease research.

•  Giving a gift to the AGA Research Foundation in memory of a loved one. A memorial gift is a meaningful way to celebrate the legacy of a family member, friend, or colleague.
•  Telling your friends and family members to donate to the AGA Research Foundation in YOUR honor.

Your next step

An honorary gift is a wonderful way to acknowledge someone’s vision for the future. To learn more about ways to recognize your honoree, visit our website at www.gastro.org/contribute or contact Harmony Excellent at 301-272-1602 or [email protected].

[email protected]

Beginning in February 2018, The New Gastroenterologist (TNG) – a supplement to GI & Hepatology News that addresses issues pertinent to trainees and early-career GIs – will switch to a primarily digital format. We are excited about this change and confident that it will allow for a more effective and widespread dissemination of content that is valuable to both AGA members and our readership more broadly.

AGA Institute

[email protected]

Beginning in February 2018, The New Gastroenterologist (TNG) – a supplement to GI & Hepatology News that addresses issues pertinent to trainees and early-career GIs – will switch to a primarily digital format. We are excited about this change and confident that it will allow for a more effective and widespread dissemination of content that is valuable to both AGA members and our readership more broadly.

AGA Institute

[email protected]

Beginning in February 2018, The New Gastroenterologist (TNG) – a supplement to GI & Hepatology News that addresses issues pertinent to trainees and early-career GIs – will switch to a primarily digital format. We are excited about this change and confident that it will allow for a more effective and widespread dissemination of content that is valuable to both AGA members and our readership more broadly.

AGA Institute

[email protected]

What will the practice of gastroenterology look like in 20 years? It is our hope that physicians will have an abundance of new tools and treatments to care for their patients suffering from digestive disorders.

How will we get there? New treatments and devices are the result of years of research.

What will the practice of gastroenterology look like in 20 years? It is our hope that physicians will have an abundance of new tools and treatments to care for their patients suffering from digestive disorders.

How will we get there? New treatments and devices are the result of years of research.

What will the practice of gastroenterology look like in 20 years? It is our hope that physicians will have an abundance of new tools and treatments to care for their patients suffering from digestive disorders.

How will we get there? New treatments and devices are the result of years of research.

Appealing step therapy protocols can be time consuming and burdensome for physicians and patients, and can takes months to resolve. The Restoring the Patient’s Voice Act (HR 2077), introduced by physicians Reps. Brad Wenstrup, R-OH, and Raul Ruiz, D-CA, would provide a clear and timely appeals process when a patient has been subjected to step therapy by their insurance provider.

AGA endorsed this legislation to provide patients with a clear, equitable and fair appeals process when subjected to step therapy protocols. AGA is working with patient advocacy groups, like the Crohn’s and Colitis Foundation, provider, and professional societies to educate members of Congress on this issue and the implications it has for patients being able to access the right treatment at the right time.
 

[email protected]

Appealing step therapy protocols can be time consuming and burdensome for physicians and patients, and can takes months to resolve. The Restoring the Patient’s Voice Act (HR 2077), introduced by physicians Reps. Brad Wenstrup, R-OH, and Raul Ruiz, D-CA, would provide a clear and timely appeals process when a patient has been subjected to step therapy by their insurance provider.

AGA endorsed this legislation to provide patients with a clear, equitable and fair appeals process when subjected to step therapy protocols. AGA is working with patient advocacy groups, like the Crohn’s and Colitis Foundation, provider, and professional societies to educate members of Congress on this issue and the implications it has for patients being able to access the right treatment at the right time.
 

[email protected]

Appealing step therapy protocols can be time consuming and burdensome for physicians and patients, and can takes months to resolve. The Restoring the Patient’s Voice Act (HR 2077), introduced by physicians Reps. Brad Wenstrup, R-OH, and Raul Ruiz, D-CA, would provide a clear and timely appeals process when a patient has been subjected to step therapy by their insurance provider.

AGA endorsed this legislation to provide patients with a clear, equitable and fair appeals process when subjected to step therapy protocols. AGA is working with patient advocacy groups, like the Crohn’s and Colitis Foundation, provider, and professional societies to educate members of Congress on this issue and the implications it has for patients being able to access the right treatment at the right time.
 

[email protected]

Marvin H. Sleisenger, MD, AGAF, of Kentfield, Calif., died at age 93 on Thursday, Oct. 19, 2017. Sleisenger served as editor of Gastroenterology from 1965 to 1970, and as president of AGA in 1976.

Sleisenger attended Harvard College and Harvard Medical School. He trained at Harvard, the University of Pennsylvania, and Cornell Medical School. During the Korean War, he served in the U.S. Naval Medical Corps. He was a member of the faculty at Cornell Medical School and in 1954, was appointed as chief of the division of gastroenterology. In 1968, he became professor and vice chairman of the department of medicine of the University of California, San Francisco and chief of the medical service at the Veterans Administration Hospital. His achievements as an outstanding educator were recognized in 1994 when he became the recipient of the AGA Distinguished Educator Award.

Marvin H. Sleisenger, MD, AGAF, of Kentfield, Calif., died at age 93 on Thursday, Oct. 19, 2017. Sleisenger served as editor of Gastroenterology from 1965 to 1970, and as president of AGA in 1976.

Sleisenger attended Harvard College and Harvard Medical School. He trained at Harvard, the University of Pennsylvania, and Cornell Medical School. During the Korean War, he served in the U.S. Naval Medical Corps. He was a member of the faculty at Cornell Medical School and in 1954, was appointed as chief of the division of gastroenterology. In 1968, he became professor and vice chairman of the department of medicine of the University of California, San Francisco and chief of the medical service at the Veterans Administration Hospital. His achievements as an outstanding educator were recognized in 1994 when he became the recipient of the AGA Distinguished Educator Award.

Marvin H. Sleisenger, MD, AGAF, of Kentfield, Calif., died at age 93 on Thursday, Oct. 19, 2017. Sleisenger served as editor of Gastroenterology from 1965 to 1970, and as president of AGA in 1976.

Sleisenger attended Harvard College and Harvard Medical School. He trained at Harvard, the University of Pennsylvania, and Cornell Medical School. During the Korean War, he served in the U.S. Naval Medical Corps. He was a member of the faculty at Cornell Medical School and in 1954, was appointed as chief of the division of gastroenterology. In 1968, he became professor and vice chairman of the department of medicine of the University of California, San Francisco and chief of the medical service at the Veterans Administration Hospital. His achievements as an outstanding educator were recognized in 1994 when he became the recipient of the AGA Distinguished Educator Award.

Dear Colleagues,

Where would clinical practice be today without GI research?

The way we diagnose and treat patients is thanks to years of research. But as you know, federal research funding is at risk. Promising, early-stage investigators find it increasingly difficult to secure funding and many leave the field because they are unable to sustain a research career.

This is bad news for digestive health patients and the clinicians who care for them.

As a member of the GI community, you understand the need to continually advance the science and practice of gastroenterology. You understand the physical, emotional, and financial costs of digestive diseases. And you understand the tremendous value of research to advance patient care.

At a time when we are on the brink of major scientific breakthroughs, there is a growing gap in federal funding for research. Many well-qualified young investigators cannot get government funding. Gifts to the AGA Research Foundation this year directly supported 52 talented investigators. Despite this success, over 200 other innovative and promising research ideas went unfunded.

I am asking you to support a cause important to me and equally important to you. You can help fill the funding gap and protect the next generation of investigators by joining me in supporting the AGA Research Foundation through a personal gift.

Every dollar is a step forward...to new treatments. To cures impacting patients’ lives. To new generations of talented investigators in digestive disease research.

Please help us continue our efforts by making your tax-deductible donation. Donate today at www.gastro.org/donate.

Thank you in advance for your support and best wishes for a happy, healthy holiday season and successful New Year.
 

Three easy ways to give

Online: www.gastro.org/donateThrough the mail:

AGA Research Foundation

4930 Del Ray Avenue

Bethesda, MD 20814

Over the phone: 301-222-4002

All gifts are tax-deductible to the fullest extent of U.S. law.

Dear Colleagues,

Where would clinical practice be today without GI research?

The way we diagnose and treat patients is thanks to years of research. But as you know, federal research funding is at risk. Promising, early-stage investigators find it increasingly difficult to secure funding and many leave the field because they are unable to sustain a research career.

This is bad news for digestive health patients and the clinicians who care for them.

As a member of the GI community, you understand the need to continually advance the science and practice of gastroenterology. You understand the physical, emotional, and financial costs of digestive diseases. And you understand the tremendous value of research to advance patient care.

At a time when we are on the brink of major scientific breakthroughs, there is a growing gap in federal funding for research. Many well-qualified young investigators cannot get government funding. Gifts to the AGA Research Foundation this year directly supported 52 talented investigators. Despite this success, over 200 other innovative and promising research ideas went unfunded.

I am asking you to support a cause important to me and equally important to you. You can help fill the funding gap and protect the next generation of investigators by joining me in supporting the AGA Research Foundation through a personal gift.

Every dollar is a step forward...to new treatments. To cures impacting patients’ lives. To new generations of talented investigators in digestive disease research.

Please help us continue our efforts by making your tax-deductible donation. Donate today at www.gastro.org/donate.

Thank you in advance for your support and best wishes for a happy, healthy holiday season and successful New Year.
 

Three easy ways to give

Online: www.gastro.org/donateThrough the mail:

AGA Research Foundation

4930 Del Ray Avenue

Bethesda, MD 20814

Over the phone: 301-222-4002

All gifts are tax-deductible to the fullest extent of U.S. law.

Dear Colleagues,

Where would clinical practice be today without GI research?

The way we diagnose and treat patients is thanks to years of research. But as you know, federal research funding is at risk. Promising, early-stage investigators find it increasingly difficult to secure funding and many leave the field because they are unable to sustain a research career.

This is bad news for digestive health patients and the clinicians who care for them.

As a member of the GI community, you understand the need to continually advance the science and practice of gastroenterology. You understand the physical, emotional, and financial costs of digestive diseases. And you understand the tremendous value of research to advance patient care.

At a time when we are on the brink of major scientific breakthroughs, there is a growing gap in federal funding for research. Many well-qualified young investigators cannot get government funding. Gifts to the AGA Research Foundation this year directly supported 52 talented investigators. Despite this success, over 200 other innovative and promising research ideas went unfunded.

I am asking you to support a cause important to me and equally important to you. You can help fill the funding gap and protect the next generation of investigators by joining me in supporting the AGA Research Foundation through a personal gift.

Every dollar is a step forward...to new treatments. To cures impacting patients’ lives. To new generations of talented investigators in digestive disease research.

Please help us continue our efforts by making your tax-deductible donation. Donate today at www.gastro.org/donate.

Thank you in advance for your support and best wishes for a happy, healthy holiday season and successful New Year.
 

Three easy ways to give

Online: www.gastro.org/donateThrough the mail:

AGA Research Foundation

4930 Del Ray Avenue

Bethesda, MD 20814

Over the phone: 301-222-4002

All gifts are tax-deductible to the fullest extent of U.S. law.

The AGA Center for GI Innovation and Technology is excited to announce a new clinical research registry to track and evaluate patient outcomes after trans-oral endoscopic suturing procedures.

The Prospective Registry for Trans-Oral Suturing Applications (“Endoscopic Suturing Registry”) will collect real-world data related to the safety and effectiveness of procedures done with Apollo Endosurgery’s OverStitch™ Endoscopic Suturing System. Jennifer Maranki, MD, director of endoscopy, Penn State Milton S. Hershey School of Medicine, and Brian Dunkin, MD, head of endoscopic surgery and medical director, Houston Methodist Institute for Technology, Innovation and Education, will serve as principal investigators for the Endoscopic Suturing Registry. The Registry will begin collecting patient data in early 2018.

We asked Michael Kochman, MD, AGAF, past chair of the AGA Center for GI Innovation and Technology and director of the Center for Endoscopic Innovation, Research and Training at the University of Pennsylvania, to weigh in on the value of this new registry.

“Flexible endoscopic suturing is an important tool for the treatment of a number of GI disorders. As these procedures become more routine in GI and surgery practices across the country, the real-world data AGA will collect through the Endoscopic Suturing Registry will guide all stakeholders in making informed decisions around the continued adoption of these procedures in clinical practice.”

Learn more about AGA’s registry initiative at www.gastro.org/patient-care/registries-studies.
 

The AGA Center for GI Innovation and Technology is excited to announce a new clinical research registry to track and evaluate patient outcomes after trans-oral endoscopic suturing procedures.

The Prospective Registry for Trans-Oral Suturing Applications (“Endoscopic Suturing Registry”) will collect real-world data related to the safety and effectiveness of procedures done with Apollo Endosurgery’s OverStitch™ Endoscopic Suturing System. Jennifer Maranki, MD, director of endoscopy, Penn State Milton S. Hershey School of Medicine, and Brian Dunkin, MD, head of endoscopic surgery and medical director, Houston Methodist Institute for Technology, Innovation and Education, will serve as principal investigators for the Endoscopic Suturing Registry. The Registry will begin collecting patient data in early 2018.

We asked Michael Kochman, MD, AGAF, past chair of the AGA Center for GI Innovation and Technology and director of the Center for Endoscopic Innovation, Research and Training at the University of Pennsylvania, to weigh in on the value of this new registry.

“Flexible endoscopic suturing is an important tool for the treatment of a number of GI disorders. As these procedures become more routine in GI and surgery practices across the country, the real-world data AGA will collect through the Endoscopic Suturing Registry will guide all stakeholders in making informed decisions around the continued adoption of these procedures in clinical practice.”

Learn more about AGA’s registry initiative at www.gastro.org/patient-care/registries-studies.
 

The AGA Center for GI Innovation and Technology is excited to announce a new clinical research registry to track and evaluate patient outcomes after trans-oral endoscopic suturing procedures.

The Prospective Registry for Trans-Oral Suturing Applications (“Endoscopic Suturing Registry”) will collect real-world data related to the safety and effectiveness of procedures done with Apollo Endosurgery’s OverStitch™ Endoscopic Suturing System. Jennifer Maranki, MD, director of endoscopy, Penn State Milton S. Hershey School of Medicine, and Brian Dunkin, MD, head of endoscopic surgery and medical director, Houston Methodist Institute for Technology, Innovation and Education, will serve as principal investigators for the Endoscopic Suturing Registry. The Registry will begin collecting patient data in early 2018.

We asked Michael Kochman, MD, AGAF, past chair of the AGA Center for GI Innovation and Technology and director of the Center for Endoscopic Innovation, Research and Training at the University of Pennsylvania, to weigh in on the value of this new registry.

“Flexible endoscopic suturing is an important tool for the treatment of a number of GI disorders. As these procedures become more routine in GI and surgery practices across the country, the real-world data AGA will collect through the Endoscopic Suturing Registry will guide all stakeholders in making informed decisions around the continued adoption of these procedures in clinical practice.”

Learn more about AGA’s registry initiative at www.gastro.org/patient-care/registries-studies.